Managing Growth Hormone Deficiency Across the Continuum of Care - Episode 10
Extension Data for Other Long-Acting GH Analogs
Weekly lonapegsomatropin shows safe, effective growth hormone therapy, but IGF-1 may run high—learn dosing insights and adult trial outcomes.
This episode reviews the trial and extension data for the two remaining FDA-approved long-acting GH analogs — somapacitan (REAL3 pediatric; REAL1 adult) and somatrogon (pediatric) — and addresses the question of whether higher IGF-1 levels seen with long-acting formulations translate to clinical difference in efficacy.
Dr. Yang presents the REAL3 trial data for somapacitan in pediatric GHD. The trial used a peak-trough-average IGF-1 methodology, yielding IGF-1 values within the −2 to +2 range. Dr. Yang poses a provocative question: if long-acting analogs produce higher average IGF-1 levels than daily GH yet achieve similar height velocities, does IGF-1 level actually drive growth outcomes, or is it merely a surrogate?
Dr. Alter confirms that across the somapacitan extension data, height velocity responses were excellent — over 7 cm/year on average. Both continued-weekly and switched-to-weekly groups performed comparably, offering reassurance that transitioning mid-treatment is safe and effective.
Dr. Agrawal then reviews the adult REAL1 trial for somapacitan (~300 patients, 34-week primary phase with 52-week extension, three arms: weekly somapacitan, daily GH, weekly placebo). Weekly somapacitan demonstrated non-inferiority to daily GH and superiority over placebo in reducing visceral adiposity and increasing lean body mass. No safety signals were identified.
The episode closes with a review of somatrogon, approved for pediatric GHD in 2023. Extension trial data show IGF-1 SDS of approximately +1.2 to +1.4, with strong efficacy and safety profiles. However, the adult somatrogon trial did not meet its primary endpoint of fat mass change, and the data remain unpublished in peer-reviewed journals. Panelists note this likely reflects study design issues rather than a true lack of biologic effect.
In the next episode, “Real-World Registry Data for Long-Acting GH Analogs — SkyBright, SkyPass, ANSWER, and Beyond,” the panel examines what real-world registries reveal about treatment patterns, safety, and outcomes in GHD, and how they compare to clinical trial findings.
